by Jen Hodson | Jun 4, 2019 | Press Releases
Phase Ib/II Clinical Trial Data Reported at 2019 Annual Meeting of the American Society of Clinical Oncology Shows High Overall Objective Response Rate (ORR) of 58% and Complete Response Rate (CR) of 33% in Relapsed/Refractory Lymphoma Patients Culver City, CA, June...
by Jen Hodson | Jun 3, 2019 | Press Releases
First engineered, GMP-grade, cryopreserved, off-the-shelf, bi-specific NK cell therapy to enter human clinical trials targeting CD16 and CD19 in patients with lymphoma Culver City, California, June 3, 2019- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation,...
by Jen Hodson | Jun 2, 2019 | Events, Press Releases
CULVER CITY, CA.- June 3, 2019 - NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong and Company management will be participating in the Jefferies 2019 Annual Healthcare...
by Jen Hodson | May 31, 2019 | Press Releases
Preclinical and Clinical Data Demonstrate Advanced Deployment of Precision Medicine Tools to Analyze and Potentially More Effectively Intervene with Highly Focused Therapeutic Interventions Culver City, May 31, 2019 – NantKwest (Nasdaq:NK), a leading clinical-stage,...
by Jen Hodson | May 15, 2019 | Events, Press Releases
CULVER CITY, CALIFORNIA- May 15, 2019 - NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company will be participating in a number of investment conferences during the month of May 2019. The...
by Jen Hodson | May 1, 2019 | Press Releases
NK-92® Cell Based Bioanalytical Solutions are the Key to Optimizing R&D and Commercial Product Development Efforts for Monoclonal Antibodies, Bi-Specifics and Related Biological ProductsSAN DIEGO–May 1, 2019- Brink Biologics, Inc., a NantKwest,...
